Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enstilar Add-on to Otezla in Plaque Psoriasis
NCT03587194Phase 4Completed
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of calcipotriol in plaque psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Primary endpoint: Psoriasis Area Severity Index 75 at 12 weeks. Started Jul 2018; status: completed.
02
Drugs
calcipotriol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03587194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587194.